If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.80    0.00 (0.00%)
Bid:
8.60
Ask:
9.00
Spread: 0.40 (4.651%)
Market Cap: £58.32m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Director Share Purchase

12 May 2021 14:50

RNS Number : 4257Y
Kromek Group PLC
12 May 2021
 

12 May 2021

 

Kromek Group plc

("Kromek" or the "Group")

 

Director Share Purchase

 

Kromek (AIM: KMK), a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, announces that Rakesh Sharma, Non-Executive Chairman, has today purchased 63,152 ordinary shares of 1 pence each in the Group ("Ordinary Shares") at a price of 15.83 pence per Ordinary Share.

 

Following this purchase, Mr Sharma has an interest in 374,856 Ordinary Shares, representing 0.09% of the issued share capital of the Group. 

 

 

For further information, please contact:

 

Kromek Group plc

 

Arnab Basu, CEO

Paul Farquhar, CFO

 

+44 (0)1740 626 060

Cenkos Securities plc (Nominated Adviser and Broker)

 

Max Hartley/Camilla Hume (NOMAD)

Julian Morse (Sales)

 

+44 (0)20 7397 8900

Luther Pendragon (PR)

 

Harry Chathli/Claire Norbury

+44 (0)20 7618 9100

 

 

About Kromek Group plc

 

Kromek Group plc is a technology group (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT") and other advanced technologies. Using its core technology platforms, Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

 

The Group's business model provides a vertically integrated technology offering to customers, from radiation detector materials to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Group has operations in the UK and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over 150 full-time employees across its global operations. Further information on Kromek Group is available at www.kromek.com and https://twitter.com/kromekgroup.

 

The Group makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Rakesh Sharma

2

Reason for the notification

a)

Position/status

Non-Executive Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Kromek Group plc

b)

LEI

213800VLHYXGHEX5VQ48

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1p each

 

 

GB00BD7V5D43

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

Price(s)

Volume(s)

15.83 pence

63,152

 

d)

Aggregated information

- Aggregated volume- Price

 

 N/A

e)

Date of the transaction

12 May 2021

f)

Place of the transaction

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEADSAFLNFEFA
Date   Source Headline
28th Feb 201912:55 pmRNSHolding(s) in Company
28th Feb 201912:55 pmRNSHolding(s) in Company
28th Feb 201912:50 pmRNSHolding(s) in Company
26th Feb 201912:56 pmRNSDirector Dealings
26th Feb 20197:00 amRNSNuclear security contract with new OEM customer
25th Feb 20191:02 pmRNSResults of General Meeting and Open Offer and TVR
7th Feb 20197:00 amRNSFirm Placing and Open Offer and Notice of GM
28th Jan 20197:00 amRNSKromek Awarded $58m Medical Imaging Contract
14th Jan 20197:00 amRNSInterim Results
18th Dec 20187:00 amRNSNotice of Results
10th Dec 20187:00 amRNSKromek awarded first biological contract by DARPA
19th Nov 20187:00 amRNSFive-year $7.8m baggage screening contract
1st Oct 20185:12 pmRNSResult of AGM and Directorate Change
27th Sep 20187:00 amRNSKromek awarded $1.8m funding from DTRA
7th Sep 20182:57 pmRNSNotice of AGM and Posting of Annual Report
20th Aug 20187:00 amRNSKromek wins two new contracts in medical division
23rd Jul 20187:00 amRNSKromek secures two contracts from US government
17th Jul 20187:00 amRNSKromek radiation detectors used during NATO Summit
2nd Jul 20187:00 amRNSFinal Results
30th May 20187:00 amRNSFive-year contract from existing medical customer
1st May 20187:00 amRNSTrading Update
23rd Apr 20187:00 amRNSAward of Molecular Breast Imaging Device project
12th Mar 20187:00 amRNSAward of $1.6m extension to contract by DARPA
11th Jan 20187:00 amRNSAppointment of Joint Broker
19th Dec 20177:00 amRNSInterim Results
27th Nov 20177:00 amRNSNotice of Results
31st Oct 20174:13 pmRNSTotal Voting Rights
13th Oct 20177:00 amRNSDirector/PDMR Shareholding
10th Oct 20179:50 amRNSDirector/PDMR Shareholding
26th Sep 201712:12 pmRNSResult of AGM
26th Sep 20177:00 amRNSDirectorate Change
19th Sep 20174:43 pmRNSExercise of Options
4th Sep 20177:00 amRNSNew five-year security screening contract
1st Sep 201710:49 amRNSNotice of AGM and Posting of Annual Report
31st Aug 201710:51 amRNSTotal Voting Rights
17th Aug 20177:00 amRNSAward of Five-Year Contract from BMD Customer
10th Jul 201712:00 pmRNSPublication of Annual Report
28th Jun 20177:00 amRNSFinal Results
12th Jun 20177:00 amRNSKromek Radiation Detectors Used During Trump Visit
1st Jun 20171:34 pmRNSTotal Voting Rights
2nd May 201712:23 pmRNSHolding(s) in Company
28th Apr 20177:00 amRNSTrading Update
5th Apr 201712:18 pmRNSBlock listing Interim Review
29th Mar 20177:00 amRNSDirector/PDMR Shareholding
7th Mar 20177:00 amRNSAward of New Contract for Radiation Detectors
22nd Feb 20177:00 amRNSFive-Year Contract in Security Screening Market
15th Feb 20174:35 pmRNSHolding(s) in Company
15th Feb 201712:54 pmRNSHolding(s) in Company
15th Feb 201712:51 pmRNSHolding(s) in Company
14th Feb 20175:40 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.